Revelation Biosciences (FRA:56U0) EV-to-Revenue : (As of May. 29, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Revelation Biosciences's enterprise value is €8.79 Mil. Revelation Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil. Therefore, Revelation Biosciences's EV-to-Revenue for today is .

The historical rank and industry rank for Revelation Biosciences's EV-to-Revenue or its related term are showing as below:

FRA:56U0's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 8.17
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-29), Revelation Biosciences's stock price is €8.88. Revelation Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00. Therefore, Revelation Biosciences's PS Ratio for today is .

Revelation Biosciences EV-to-Revenue Historical Data

The historical data trend for Revelation Biosciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences EV-to-Revenue Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Revelation Biosciences's EV-to-Revenue

For the Biotechnology subindustry, Revelation Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Revelation Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revelation Biosciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Revelation Biosciences's EV-to-Revenue falls into.

Revelation Biosciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Revelation Biosciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	8.788	/	0
	=

Revelation Biosciences's current Enterprise Value is €8.79 Mil.
Revelation Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Revelation Biosciences (FRA:56U0) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Revelation Biosciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	8.88	/	0
	=

Revelation Biosciences's share price for today is €8.88.
Revelation Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

Revelation Biosciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines